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Introduction
Thyroid nodules are a common clinical finding, with a 
prevalence at physical examination of 1% to 5% (1-5), and of 
20% to 70% at ultrasound (US) examination (2,3,6-9). The 
prevalence is higher in women and it tends to increase with 
age, impaired iodine intake or ionizing radiation exposure (8).
As less of 10% of detected nodules are malignant, the 
vast majority of cases can be managed conservatively 
(i.e., clinical and US follow up). Nevertheless, a growing 
nodule can determine compression on structures around 
the thyroid gland (i.e., esophagus, trachea), leading to 
hoarseness, dyspnea, discomfort or cosmetic issues. This is 
why a debulking treatment can be proposed, even in benign 
cases (8).
Surgery is a valuable treatment, but it carries a number of 
possible complications, such as postoperative hypothyroidism, 
compressive hematomas, recurrent laryngeal nerve injuries as 
well as risks typically connected with general anesthesia (2). 
Furthermore, quality of life of patients who undergo surgical 
treatment may be impaired by life-long dependence of 
thyroxine substitutive therapy, subtle metabolic changes and 
presence of a neck scar (6).
For these reasons, in the last decade, percutaneous 
ablation techniques [i.e., laser therapy and radiofrequency 
ablation (RFA)] have been proposed to treat thyroid 
nodules. They aimed to reduce invasiveness, morbidity, 
complication rate, hospitalization time and patient’s 
discomfort, if compared to surgery (10,11).
Year by year, different authors proposed various 
percutaneous approaches to thyroid lesions (12,13). Our 
aim is to focus on different types of needles that can be 
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used to perform RFA because, even if based on common 
principles, they all have specifics and it is still under debate 
whether different materials can modify the outcome of the 
procedure.
RFA
RFA of thyroid lesions is usually performed under local 
anesthesia, with patient in a supine position and with neck 
extension (3,14). Local anesthesia has to be preferred to 
general anesthesia because it allows a real time monitoring 
of sudden pain and/or voice changes that should induce the 
operator to stop the procedure (15). RFA is carried out with 
an external radiofrequency generator probe, combined with 
an electrode needle placed in the target tissue. The ablation 
is due to high frequency electric current ranging between 
200 and 1,200 KHz and producing an alteration on tissue 
ions, that leads to protein denaturation, blood coagulation 
and final coagulative necrosis of the target area (16,17).
Energy delivered during ablation is responsible for the 
temperature reached in the tissue and consequently for the 
extension of necrosis. Thus, the generator has to be set in 
relation to the presence of vulnerable structures near the 
target lesion, considering that the higher is the temperature 
reached by the tip, the larger will be the area of necrosis 
around the needle. Nevertheless, a minimum temperature 
of 50–80 ℃ for a number of minutes is generally needed to 
achieve a satisfactory result (18-23).
Different techniques have been proposed to perform 
RFA on a thyroid lesion. The needle’s tip can be positioned 
along the long axis of the nodule (craniocaudal approach) 
or from the medial to the lateral part of the nodule with 
transverse US image (trans-isthmic approach). The second 
one is usually preferred because it allows a better control 
of the needle’s tip and it reduces risk of complications, as 
laryngeal recurrent nerve and esophagus are less exposed 
(10,24) (Figures 1-3).
Treatment with RFA is mainly proposed for benign 
nodules even though, in recent years, the possibility of 
treating malignant lesions has been considered, especially 
for patients at high risk of surgical complications or that 
decline surgery (25). Good results have been achieved 
with RFA performed in patients with tumor persistence or 
recurrence after initial surgical treatment (26).
Needles
Different approaches have been proposed to carry out RFA 
Figure 1 Ultrasound appearance of a massive nodule of the left 
thyroid lobe that replaces all the normal glands.
Figure 2 RFA of the thyroid nodule with a trans-isthmic approach. 
The needle (asterisks) is inserted into the lesion. The delivered 
energy creates a hyperechoic shadow due to microbubbles (arrow).
Figure 3 One month follow up shows the normal thyroid lobe 
(solid arrows) with the residual nodule decreasing in size (open 
arrow).
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of thyroid nodules. Two main options can be considered: 
the one with thinner needles (18–19 G) (27) and the one, 
less used, with needles of 14 to 17 G (28).
Considering the shape and dimensions of the thyroid, 
specific thinner internally cooled multi tined needles 
(18–19 G) have been developed to minimize tissue injury and 
to easily move the needle itself within the lesion (Figure 4). 
Nevertheless, thin needles have been often addressed to 
have low visibility under US guidance, leading to difficulties 
in controlling position and deepness of the distal tip (14). 
This limitation has to be considered when nodules are deep 
or close to other structures not intended to be involved in 
the ablation (such as vessels, laryngeal nerve, oesophagus).
On the other hand, larger needles (14–17 G), with 
1-cm straight active internally cooled electrode, can be 
better visualized during the procedure and they allow 
ablation of wider areas, without moving the needle during 
the procedure. Nevertheless, the ablation zone is less 
controllable with this needle, so it should be preferred for 
isolated and bigger lesions (28).
In the last years, many papers regarding RFA on 
thyroid nodules have been produced. They mainly dealt 
with ablation of benign nodules, even though some 
series regarding ablation of malignant lesions have been 
presented.
After preliminary experiences with 14 G needles, the 
main part of literature focused on thinner and shorter 
instruments as they are considered more suitable to 
approach the thyroid gland.
Sung et al. (29) reported 44 patients with single thyroid 
nodules (23 toxic and 21 pre-toxic) ablated with a 18-gauge 
needle with an internally cooled electrode with active tips 
of various size (5, 10, 15 mm). The needle was 7 cm long 
as, considering the subcutaneous position of the thyroid 
gland, no further length is needed. Moreover, a short 
shaft allows a better control of the instrument during the 
procedure. To overcome the low visibility of the needle, the 
operator started the ablative procedure from the deepest 
part of the nodule, in order to decrease the interference 
on the US signal due to microbubbles produced during 
ablation. The mean number of radiofrequency sessions for 
each patient was 1.8±0.9 and the authors did not report any 
characteristic of the lesion that let the radiologist choose 
for one tip or another, even though different amount of 
energy (watts) are reported for any tip. We can suppose 
that the choice depended on the size and composition (solid 
or cystic) of the nodule. Moreover, the authors did not 
report major complications and the procedure was safely 
ended in every case, even though each patient experienced 
a certain grade of pain or sensation of heat on the neck and 
in the surrounding structures. Despite that, all patients 
were discharged after a couple of hours of observation 
and 24-month follow up showed a mean nodule volume 
reduction of 79.4%.
As previously mentioned, the first to describe the use 
of a modified needle for RFA of thyroid was Baek in 
2009 (30), who developed a 7 cm-shaft/18 G-diameter 
needle. This electrode, shorter and thinner than the ones 
used before, allows a better control of the procedure but 
reduces the ablated area. So, the author himself proposed 
the so called moving-shot technique, by radially moving 
the electrode inside the lesion, in order to create multiple 
spots of ablation and to reach the whole nodule from a 
single puncture site. In the first presented series (25), 
the technique, which Baek reported to last no more than 
22 minutes, induced a statistically significant reduction of 
the dimension of the nodules, without major complication. 
All patients went home after 2 hours of supervision. 
More recently, Lim et al. (26) treated patient with recurrent 
papillary carcinomas of the thyroid. As the lesion were 
generally small in size (mean diameter 0.79±0.43 cm), 
the authors modified the commercial needles, creating an 
internally cooled electrode of 7 cm of shaft, with 19 G of 
diameter and various dimensions of the tip (0.5, 0.7 and 1 cm). 
The tip was chosen in relation to the size of the lesion, 
being certain to avoid damage on any surrounding structure. 
Moreover, when the distance between the lesion and any 
vital structure was less than 5 mm, a dextrose solution was 
injected with a 23 G needle, in order to prevent unwanted 
damages. All procedures were carried out under conscious 
sedation. Furthermore, the ablation always began with 10 W 
of power and it was increased only if no hyperechoic images 
Figure 4 Needle for thyroid RFA: 7 cm shaft (white line), 
18 Gauges  of  d iameter  and 1 cm t ip  (aster isks) .  RFA, 
radiofrequency ablation.
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appeared within 10 seconds from the beginning of the 
procedure. Conversely, the power was reduced in case of 
pain or discomfort for the patient. Also in this case, the 
moving shot technique was applied when appropriate (i.e., 
when a single focus of ablation was not sufficient to destroy 
the entire lesion). Clinical results were excellent, as 82% of 
lesions disappeared completely after treatment. Nevertheless, 
the author reported 3 patients (7.7%) who had voice 
changes within 24 hours after the procedure (but resolved 
spontaneously within 2 months). Even though the percentage 
and entity of complications is still low, it appears higher than 
the already cited series, demonstrating a certain criticism in 
treating this specific type of lesions.
On the other side, some groups have reported series of 
patients treated with needles of a greater diameter (up to 
14 G). Deandrea et al. (28) reported their experience with a 
14 G needle used to treat 33 benign nodules of 31 patients 
not suitable for surgery. In this case, the approach to the 
lesion was slightly different and some issues should be 
discussed. First of all, as a 14 G needle is too traumatic to 
pass through the skin, all patients needed a surgical incision 
of about 5 mm to let the needle reach the nodule. The 
patient has to be previously informed about the cosmetic 
issues related with this type of needle as, even though of 
little concern, can be cause of discomfort in some cases. 
Secondly, due to needle dimensions, the moving shot 
technique could not be used. So, a single access was chosen 
case by case, depending on the position of the lesion and, 
when it was too big in size and one single point of ablation 
was not sufficient to treat the entire nodule, the needle had 
to be retracted and reinserted cranially, to end the ablation. 
Another issue is related to the structure of the needle. 
In fact, it was created with nine prongs that allowed the 
operator to reach a wider portion of the gland, ensuring 
a better distribution of heat in the nodule. Nevertheless, 
the distribution of each prong within the gland had to be 
carefully checked with US, as the operator had to be sure 
that extensions were far enough from thyroid’s capsule 
(i.e., 10 mm) and from vital surrounding structures (i.e., 
15 mm) to avoid any unwanted ablation. Almost all patient 
experienced mild edema after the procedure, but steroids 
were administered only three times and all other cases 
resolved spontaneously. At follow up, the mean reduction 
of volume was 50.7% with a general improvement of 
symptoms.
This kind of needle presents advantages and disadvantages 
when compared to smaller ones (i.e., 18–19 G). In fact, 
smaller needles can be moved easier within the lesion and 
they can be better monitored if compared to the prongs. 
So, thinner needles can be used for smaller lesions but, 
conversely, 14 G needles allow a faster and more effective 
ablation of bigger. In the presented paper, nodules’ size 
ranged between 20 and 73 mm in diameter. This range of 
dimensions justifies the use of larger needles. Nevertheless, 
in common clinical practice, the operators may need to be 
more precise in order to deal with smaller nodules. In fact, as 
a consequence, the use of 14 G needles tends to decrease and 
few series have been reported in the last years.
More recently, Faggiano et al. (31) reported a series of 40 
patients with compressive benign thyroid nodules, dividing 
the population in two groups: the first one was treated with 
RFA, using a 14 G needle, and the second one was only 
observed. The study confirmed that group treated with RFA 
had a significant reduction of nodule volume (from 13.3±1.8 
to 1.8±0.3 mL at 12 months follow up) and improvement of 
symptoms. In this case, the needle had only 4 prongs, with 
an expansion of 4 cm opened within the lesion under US 
control. Each session of treatment lasted 5–7 minutes and it 
was well tolerated in every case, as patients reported only a 
moderate sense of heat in the neck during the procedure. 
Conclusions
RFA is nowadays an established treatment to manage 
patients with thyroid nodules. RFA has shown excellent 
results and few complications compared with surgery, and 
today it represents an excellent option. RFA can be used to 
treat both benign thyroid nodules and recurrent thyroid 
cancers but it is not yet considered as a first line treatment 
for thyroid malignancies (32-35).
To summarize the result of our review, thinner 
internally cooled multi tined needles (18–19 G) carry 
less complications and excellent results, even though the 
procedure is longer and the needle is less visible, especially 
when dealing with deep caudal nodules.
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